Randomized, Open-Label, Phase III Trial Of Pazopanib Versus Sunitinib In First-Line Treatment Of Patients With Metastatic Renal Cell Carcinoma (MRCC): Results of the Comparz Trial

Journal article

Peer reviewed

R Motzer, T.E Hutson, J Reeves, R Hawkins, J Guo, P Nathan, M Staehler, P de Souza, J.R Merchan, K Fife, …

Annals of oncology, Vol.23, p.ixe13

2012-09

Metrics

6 Record Views

Title: Randomized, Open-Label, Phase III Trial Of Pazopanib Versus Sunitinib In First-Line Treatment Of Patients With Metastatic Renal Cell Carcinoma (MRCC): Results of the Comparz Trial
Creators: R Motzer
T.E Hutson
J Reeves
R Hawkins
J Guo
P Nathan
M Staehler
P de Souza
J.R Merchan
K Fife
J Jin
R Jones
H Uemura
U De Giorgi
U Harmenberg
J Wang
D Cella
L McCann
K Deen
T.K Choueiri
Publication Details: Annals of oncology, Vol.23, p.ixe13
Academic Unit: Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
Language: English
Resource Type: Journal article
Record Identifier: 991031598003502976